AtaiBeckley (ATAI) Income from Non-Controlling Interests (2020 - 2026)
AtaiBeckley's quarterly Income from Non-Controlling Interests came in at -$20000.0 in Q1 2026, up 41.18% year-on-year from -$14166.7 in Q1 2025, and up 41.18% quarter-over-quarter from -$34000.0 in Q1 2025.
AtaiBeckley's Income from Non-Controlling Interests history runs 6 years deep, the most recent figure standing at -$24000.0 for Q3 2025.
- In Q3 2025, Income from Non-Controlling Interests rose 4.0% year-over-year to -$24000.0; the TTM figure through Sep 2025 stood at -$108000.0 (up 93.24% YoY), while the FY2024 annual figure was -$780000.0, up 78.75% from the prior year.
- Income from Non-Controlling Interests for Q1 2026 stood at -$20000.0, up from -$34000.0 in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was -$20000.0 in Q1 2026, with the low at -$34000.0 in Q1 2025.
- A 5-year average of -$615666.7 and a median of -$677000.0 in 2022 frame the typical range for Income from Non-Controlling Interests.
- Across the five-year window, Income from Non-Controlling Interests slumped 48500.0% in 2021 and surged 97.14% in 2024, its largest moves.
- AtaiBeckley's Income from Non-Controlling Interests stood at -$4.4 million in 2021, then surged by 62.74% to -$1.6 million in 2022, then jumped by 48.11% to -$850000.0 in 2023, then jumped by 96.12% to -$33000.0 in 2024, then advanced by 27.27% to -$24000.0 in 2025.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered -$24000.0, -$17000.0, and -$34000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.75 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | AtaiBeckley | 1.62 Bn | 1.62 Bn | - | -20,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20,000.00 |
| Sep 30, 2025 | -24,000.00 |
| Jun 30, 2025 | -17,000.00 |
| Mar 31, 2025 | -34,000.00 |
| Mar 31, 2025 | -34,000.00 |
| Dec 31, 2024 | -33,000.00 |
| Sep 30, 2024 | -25,000.00 |
| Jun 30, 2024 | -57,000.00 |
| Mar 31, 2024 | -665,000.00 |
| Dec 31, 2023 | -850,000.00 |
| Sep 30, 2023 | -873,000.00 |
| Jun 30, 2023 | -729,000.00 |
| Mar 31, 2023 | -1.22 Mn |
| Dec 31, 2022 | -1.64 Mn |
| Sep 30, 2022 | -1.81 Mn |
| Jun 30, 2022 | -891,000.00 |
| Mar 31, 2022 | -689,000.00 |
| Dec 31, 2021 | -4.40 Mn |
| Sep 30, 2021 | -484,000.00 |
| Mar 31, 2021 | 3.36 Mn |
| Dec 31, 2020 | -7.76 Mn |
| Sep 30, 2020 | 1,000.00 |
| Jun 30, 2020 | -109,000.00 |